Sign in
Taking peoplePhase 3

OLE Study With Filgotinib in JIA

Key facts

Who runs it
Alfasigma S.p.A.
Where
Belgium, Czechia, France, Germany, Greece, Hungary, Italy, Poland, Spain, and United Kingdom39 sites in 10 countriesChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
80 people, planned
Started
20 Apr 2026
Expected to end
Dec 2027
Type of study
Interventional
Treatments tested
  • Filgotinib
Record updated
10 August 2026

Who can take part

Age
8 years to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Subject must have completed treatment with filgotinib in at least one parent study and achieved a clinical benefit at the end of the parent protocols
  • Subject and/or parent/legal guardian must be able and willing to comply with the clinical study protocol requirements and must sign and date the informed consent form and assent (if required per local regulation) as approved by the Independent Ethics Committee/ Institutional Review Board, prior to any protocol evaluations
  • Female or male subject 8 to <18 years of age, on the date of signing the informed consent and assent (per local regulation) form
  • Female subject of childbearing potential who is sexually active and at risk for pregnancy must agree to use contraception/preventive exposure measures as described in the clinical study protocol

Who cannot take part

  • Development of any condition during the parent study that would preclude safe continuation
  • Active infection that is clinically significant, as per Investigator's judgement
  • Subject with known hypersensitivity to the components of potential study therapy
  • Subjects with any condition or circumstances (including abnormalities in laboratory parameters) that, in the opinion of the investigator, may make a subject unlikely or unable to complete the study or comply with study procedures and requirements
  • Pregnancy

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 8 and 18 years old?

This trial has no sites in United States.

It has sites in 10 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This OLE study is designed to evaluate long-term safety, tolerability, and efficacy of filgotinib in patients with polyarticular or systemic juvenile idiopathic arthritis (pJIA-sJIA) who have completed the treatment period/prolonged treatment period of the parent studies and demonstrated clinical benefit defined as control of disease activity through improvement in signs and symptoms as per Investigator judgement.

The group in the trial

  • FilgotinibTreatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Open-label Extension (OLE), Multiple Dose Study to Evaluate Safety, Tolerability, and Efficacy of Filgotinib in Children and Adolescents From 8 Years to Less Than 18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Fit questions
Built from NCT07553182, who can take part
Record updated
10 August 2026